Effectiveness and hepatotoxicity of statins in men seropositive for hepatitis C virus

Pharmacotherapy

Volumn 27, Issue 6, 2007, Pages 845-851

  Segarra Newnham, Marisel ^a   Parra, David ^a   Martin Cooper, Ellen M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

HCV; Hepatitis C; Hepatotoxicity; Liver toxicity; Side effects; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EVALUATION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MYALGIA; REGISTER; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; STOMACH UPSET;

AGED; ALANINE TRANSAMINASE; CHOLESTEROL, LDL; CORONARY DISEASE; HEPATITIS C; HEPATITIS C ANTIBODIES; HOSPITALS, VETERANS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 34249787036     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.6.845     Document Type: Review

References (29)

1. Thom T, Haase N, Rosamond W, et al. Heart and stroke statistics: 2006 update. Circulation 2006;113:85-151. (Erratum in Circulation 2006;113:696.)
2. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol level: results of AFCAPS/TexCAPS. JAMA 1998;279:1616-22.
3. Sheperd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7.
4. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 1994;344:1383-9.
5. Sacks FM, Pfeffer MA, Lemuel MA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-9.
6. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. Final conclusions and recommendations of the National Lipid Association statin safety assessment task force. Am J Cardiol 2006;97(suppl):89C-94.
7. FDA Working Group. CDER-PhRMA-AASLD conference 2000: clinical white paper on drug-induced hepatotoxicity, November 2000. Available from http://www.fda.gov/cder/livertox/clinical .pdf. Accessed December 11, 2006.
8. Strader DB, Wright T, Thomas DL, Seeff LB. AASLD practice guideline: diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
9. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-14.
10. Dominitz JA, Boyko EJ, Koepsell TD, et al. Elevated prevalence of hepatitis C infection in users of United States veteran medical centers. Hepatology 2005;41:88-96.
11. Roselle GA, Danko LH, Kralovic SM, Simbarti LA, Kizer KW. National hepatitis C surveillance day in the Veterans Health Administration of the Department of Veterans Affairs. Mil Med 2002;167:756-9.
12. Department of Veterans Affairs. National hepatitis C program. practice recommendations. Available from http://www. hepatitis.va.gov/vahep?page=prtop04- gd-2006-02. Accessed December 20, 2006.
13. Tolman KG. The liver and lovastatin. Am J Cardiol 2002;89:1374-80.
14. De Denus S, Spinler SA, Miller K, Peterson AM. Statins and liver toxicity: a meta-analysis. Pharmacotherapy 2004;24:584-91.
15. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000;23:197-213.
16. Hulley SB, Grady D, Browner WS. Statins: underused by those who would benefit [editorial]. BMJ 2000;321:971-2.
17. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998;81:582-7.
18. Pasternak RC, Smith SC, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002;40:567-72.
19. Gotto AM. Safety and statin therapy: reconsidering the risks and benefits [editorial]. Arch Intern Med 2003;163:657-9.
20. Ewing JA. Detecting alcoholism: The CAGE questionnaire. JAMA 1984;252:1905-7.
21. Chalasani N, Aliadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126:1287-92.
22. Chalasani N, Hall SD. Statin-induced hepatotoxicity [letter]. Gastroenterology 2004;127:1278-9.
23. Gibson K, Rindone JP. Experience with statin use in patients with chronic hepatitis C infection. Am J Cardiol 2005;96:1278-9.
24. Khorashadi S, Hasson NK, Cheung RC. Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006;4:902-7.
25. Roberts WC. Getting more people on statins [editorial]. Am J Cardiol 2002;90:683-5.
26. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2004;41:690-5.
27. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006;101:76-82.
28. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731-9.
29. Cohen DE, Anania FA, Chalasani N. An assessment of statin safety by hepatologists. Am J Cardiol 2006;97(suppl):77C-81.